References
- Scottish Intercollegiate Guidelines Network. Management of osteoporosis—A National Clinical Guideline. SIGN 71 June, 2003
- Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J 1991; 303: 13–16
- Hickey M, Fraser I. The contraceptive use of depot medroxyprogesterone acetate. Clin Obstet Gynecol 1995; 38: 849–848
- Naessen T, Olsson S-E, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995; 52: 35–39
- Cromer B A, McArdle Blair J, Mahan J D, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996; 129: 671–676
- Taneepanichskul S, Intaraprasert S, Theppisai U, et al. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate: a cross-sectional study of Thai women. Contraception 1997; 56: 153–155
- Taneepanichskul S, Intaraprasert S, Theppisai U, et al. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception 1997; 56: 1–3
- Gbolade B, Ellis S, Murby B, et al. Bone density in long-term users of DMPA. BJOG 1998; 105: 90–94
- Cundy T, Cornish J, Evans M C, et al. Recovery of bone density in women who stop using depot medroxyprogesterone acetate. Br Med J 1994; 308: 247–248
- Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen University Press. 1991
- Nguyen T V, Jones G, Sambrook P N, et al. Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures. J Clin Endocrinol Metab 1995; 80: 2709–2714
- Law M R, Hackshaw A K. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. Br Med J 1997; 314: 841–846
- Orr-Walker B J, Evans M C, Ames R W, et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol 1998; 49: 615–618
- MacInnis R J, Cassar C, Nowson C A, et al. Determinants of bone density in 30- to 65-year old women: a co-twin study. J Bone Min Res 2003; 18: 1650–1656
- Berenson A B, Radecki C M, Grady J J, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001; 98: 576–582
- Scholes D, LaCroix A Z, Ichikawa L E, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13: 581–587
- Cundy T, Cornish J, Roberts H, et al. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 2002; 186: 978–983
- Gbolade B A. Depo-Provera and bone density. J Fam Plan Reprod Health Care 2002; 28: 7–11
- Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG 2001; 108: 1214–1221
- Cromer B. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol 2003; 15: 353–357
- Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003; 68: 75–87
- Zibners B A, Cromer B A, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol 1999; 12: 90–94